J&J reports 75% tumor response rate with novel prostate cancer therapy

Johnson & Johnson's experimental prostate cancer drug, JNJ-6143, showed significant PSA level declines and tumor shrinkage in an early-stage trial. Among 31 patients, 77% had at least a 50% PSA reduction, and 69% had a confirmed tumor response. The drug was acquired through J&J's US$3.05 billion purchase of Halda Therapeutics. Common side effects included nausea and elevated cholesterol. Results were presented at the European Society for Medical Oncology Congress.

Johnson & Johnson reported a 75% response rate in its 50-mg Phase 1 trial for prostate cancer drug JNJ-6143, with 12 of 16 patients showing confirmed tumor responses. The company is advancing the drug to a Phase 2 trial, which began recruiting on Sept. 16. JNJ-6143 targets BRD4 and the androgen receptor, proteins linked to prostate cancer.

Johnson & Johnson shares rose after Phase 1 results showed its experimental prostate cancer drug JNJ-6143 achieved a 75% response rate in advanced patients. Microsoft announced voluntary buyouts for 60,000 employees, seen as operational optimization rather than a slowdown. Meta Platforms plans a $95B equity raise, SpaceX a $40B debt raise, and Anthropic filed for an IPO. AI-related stocks rebounded, while defensive sectors saw profit-taking.

Johnson & Johnson (JNJ) reported early-stage trial results for its experimental prostate cancer drug, JNJ-6143, showing 75% of patients experienced tumor shrinkage or disappearance. The drug, acquired via a $3.05B deal, uses novel technology and is being tested in a difficult-to-treat population. JNJ plans Phase 2 testing at a 50-milligram dose, where 77% of patients saw PSA level reductions.

Johnson & Johnson's prostate cancer drug JNJ-6143, acquired from Halda Therapeutics, showed a 75% overall response rate in early-stage trials. Analysts at Leerink Partners called the results 'immaculate' and highlighted its potential as a best-in-class therapy. The drug is being tested in patients with metastatic castration-resistant prostate cancer, with a preliminary optimal dose of 50 mg identified.

Johnson & Johnson (JNJ) reported Phase 1b/2 study results showing that RYBREVANT FASPRO combined with pembrolizumab and carboplatin achieved a 77% response rate in patients with recurrent or metastatic head and neck cancer. The trial involved 22 patients, with 14% experiencing complete responses. JNJ's stock closed at $263.81 on October 23, 2026, and was up 1.00% in pre-market trading.